Newsfeeds Archive - Spark Newswire

4 minute read

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze For The Treatment Of Acute Lymphoblastic Leukemia And Lymphoblastic Lymphoma

Yesterday, 9:01 AM

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Jazz Pharmaceuticals plc (NASDAQ:JAZZ), ("Jazz") has been granted marketing authorization by the European Commission (EC) for Enrylaze®

JAZZ

4 minute read

Cannabis Industry Changes As Marijuana Rescheduling Looms

By Jelena Martinovic

September 15, 9:02 AM

As the Benzinga Cannabis Capital Conference returns to Chicago this Sept 27-28 for its 17th edition, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the top leadership changes ove

ACB

2 minute read

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years

By Lara Goldstein

September 12, 4:35 PM

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

ATAI

3 minute read

Epidiolex Counterpart Debuts In Brazil’s Cannabis Market As Its Maker Eyes TSX IPO

By Javier Hasse

August 23, 3:57 PM

Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, Anvisa) in July.

JAZZ

2 minute read

Jazz Pharmaceuticals’ Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target

By Nabaparna Bhattacharya

August 14, 3:24 PM

Cantor Fitzgerald analyst Charles C.

JAZZ

3 minute read

Cannabis Stock Gainers And Losers From August 11, 2023

By Benzinga Insights

August 11, 5:30 PM

GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.0001 StateHouse Hldgs (OTC:STHZF) shares closed up 111.86% at…

AAWH

2 minute read

Analyst Ratings

Expert Ratings for Jazz Pharmaceuticals

By Benzinga Insights

August 10, 2:00 PM

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

JAZZ

2 minute read

Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?

By Joana Scopel

August 9, 7:37 PM

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year.

JAZZ

22 minute read

Earnings

Earnings Scheduled For August 9, 2023

By Benzinga Insights

August 9, 4:54 AM

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.

AADI

4 minute read

GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job

By Nina Zdinjak

July 28, 9:53 AM

For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products.

JAZZ